Myleran

Q: What is paraplatin used for?

<p>Paraplatin is a medication used to treat <a href="https://www.withpower.com/clinical-trials/ovarian-cancer">ovarian cancer</a>, as well as other types of cancer such as lung, head and neck, endometrial, esophageal, bladder, breast, and <a href="https://www.withpower.com/clinical-trials/cervical-cancer">cervical cancer</a>. It is also used to treat central nervous system or germ cell tumors, osteogenic <a href="https://www.withpower.com/clinical-trials/sarcoma">sarcoma</a>, and to prepare for a stem cell or bone marrow <a href="https://www.withpower.com/clinical-trials/transplant">transplant</a>.</p>

conditioning regimens for allogeneic stem cell transplantation therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Thrombocythemia, Essential + 2 more

Treatment

3 FDA approvals

20 Active Studies for Myleran

Treatment for

conditioning regimens for allogeneic stem cell transplantation therapy

What is Myleran

BusulfanThe Generic name of this drug

Treatment SummaryBusulfan is a medication used to reduce the activity of bone marrow, usually prescribed as a palliative treatment for chronic myeloid leukemia. Although it provides relief of symptoms, it does not bring about permanent remission. The National Toxicology Program has classified busulfan as a known carcinogen.

Myleranis the brand name

Myleran Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Myleran

Busulfan

1985

Approved as Treatment by the FDA

Busulfan, also known as Myleran, is approved by the FDA for 3 uses including allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia and Leukemia, Myelogenous, Chronic, BCR-ABL Positive .

allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia

Used to treat allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia in combination with Cyclophosphamide

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Used to treat allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia in combination with Cyclophosphamide

conditioning regimens for allogeneic stem cell transplantation therapy

Used to treat conditioning regimens for allogeneic stem cell transplantation therapy in combination with Cyclophosphamide

Effectiveness

How Myleran Affects PatientsBusulfan is a drug used to treat cancer and belongs to a class of drugs called alkylating agents. These drugs work by attaching alkyl groups to certain molecules, which prevents cells from replicating and dividing. In addition, alkylating agents can alter the coding of DNA, which can lead to cell death. It is believed that the overexpression of a certain enzyme (MGST2) may make some people resistant to busulfan, although the exact role of MGST2 in busulfan metabolism is unknown.

How Myleran works in the bodyBusulfan works by damaging DNA. When it enters the cell, it is broken down and releases two carbonium ions. These ions then attach to and damage DNA molecules, preventing the cell from making copies of itself and reproducing. The damage caused by busulfan is irreversible and the cell eventually dies.

When to interrupt dosage

The recommended measure of Myleran is contingent upon the identified condition, such as Polycythemia Vera (PV), conditioning regimens for allogeneic stem cell transplantation therapy and Leukemia. The quantity of dosage depends on the technique of delivery, as outlined in the table beneath.

Condition

Dosage

Administration

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

2.0 mg, , 6.0 mg/mL, 60.0 mg

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intravenous, Solution, Solution - Intravenous, Tablet - Oral, Tablet, Injection - Intravenous, Injection, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution

Polycythemia Vera

2.0 mg, , 6.0 mg/mL, 60.0 mg

conditioning regimens for allogeneic stem cell transplantation therapy

2.0 mg, , 6.0 mg/mL, 60.0 mg

Thrombocythemia, Essential

2.0 mg, , 6.0 mg/mL, 60.0 mg

Leukemia

2.0 mg, , 6.0 mg/mL, 60.0 mg

Warnings

Myleran has one contraindication and should not be administered in conjunction with any of the states listed in the table below.Myleran Contraindications

Condition

Risk Level

Notes

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Do Not Combine

There are 20 known major drug interactions with Myleran.

Common Myleran Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Busulfan is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Busulfan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Busulfan is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Busulfan is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Busulfan is combined with Aldosterone.

Myleran Toxicity & Overdose RiskSigns of an overdose on ibuprofen include an allergic reaction, signs of internal bleeding, sudden weakness or exhaustion, persistent coughing or difficulty breathing, stomach or joint pain, severe nausea or diarrhea, dizziness or confusion, skin discoloration, and chills. In serious cases, a person may faint or even lose consciousness.

image of a doctor in a lab doing drug, clinical research

Myleran Novel Uses: Which Conditions Have a Clinical Trial Featuring Myleran?

56 active clinical trials are underway to investigate the potential of Myleran to ameliorate Thrombocythemia, Essential Leukemia and Polycythemia Vera (PV).

Condition

Clinical Trials

Trial Phases

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

0 Actively Recruiting

Leukemia

37 Actively Recruiting

Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1

Thrombocythemia, Essential

15 Actively Recruiting

Phase 1, Phase 2, Phase 3

Polycythemia Vera

0 Actively Recruiting

conditioning regimens for allogeneic stem cell transplantation therapy

0 Actively Recruiting

Myleran Reviews: What are patients saying about Myleran?

5Patient Review

8/27/2016

Myleran for Type of Leukemia - Chronic Myelogenous Leukemia

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about myleran

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is myleran used for?

"Myleran is a medication used to improve the quality of life and relieve cancer symptoms for people with chronic myelogenous leukemia. It is classified as an alkylating agent."

Answered by AI

What is busulfan used for?

"Busulfan is used in combination with cyclophosphamide to prepare a person for allogeneic hematopoietic progenitor cell transplantation, which is a treatment for chronic myelogenous leukemia. Busulfan is an alkylating agent, a group of medicines that work by causing changes in the DNA of cells."

Answered by AI

What is paraplatin used for?

"Paraplatin is a medication used to treat ovarian cancer, as well as other types of cancer such as lung, head and neck, endometrial, esophageal, bladder, breast, and cervical cancer. It is also used to treat central nervous system or germ cell tumors, osteogenic sarcoma, and to prepare for a stem cell or bone marrow transplant."

Answered by AI